Tesamorelin vs CJC-1295 + ipamorelin
All three raise the body's own growth hormone. Tesamorelin is an FDA-approved GHRH analog with phase 3 trials in more than 800 people, where it cut visceral fat by about 15%. CJC-1295 and ipamorelin are not approved; their human data is limited to small early studies, and ipamorelin remains on the FDA's compounding safety-risk list.[1,2,3,4]
7 sources, every number linked. PepDose sells no peptides and takes no vendor money.
At a glance
How do Tesamorelin and CJC-1295 + Ipamorelin compare?
No trial has compared tesamorelin with CJC-1295 or ipamorelin. The studies measured different things in different people.
| Tesamorelin | CJC-1295 + Ipamorelin | |
|---|---|---|
| What it is[5,3,6] | TesamorelinA stabilised version of the full 44-amino-acid GHRH molecule | CJC-1295 + IpamorelinCJC-1295: a modified GHRH analog. Ipamorelin: a five-amino-acid ghrelin-receptor agonist |
| Receptor | TesamorelinGHRH receptor | CJC-1295 + IpamorelinGHRH receptor (CJC-1295) and ghrelin receptor (ipamorelin) |
| FDA status[5,4] | TesamorelinApproved (2010) as Egrifta for HIV-associated excess belly fat | CJC-1295 + IpamorelinNeither is approved; ipamorelin remains on the FDA compounding safety-risk list |
| Largest human studies[1,2,3,7] | TesamorelinPhase 3: 412 people, and 806 pooled across two trials | CJC-1295 + IpamorelinCJC-1295: small studies in healthy adults. Ipamorelin: 114 surgical patients (phase 2) |
| Headline result[1,3] | TesamorelinVisceral fat −15.2% at 26 weeks (placebo +5.0%) | CJC-1295 + IpamorelinGrowth hormone up 2 to 10 times for 6 days or more after one CJC-1295 (with DAC) injection |
| IGF-1[1,3] | TesamorelinRose by about 81% | CJC-1295 + IpamorelinRose 1.5 to 3 times for 9 to 11 days (CJC-1295 with DAC) |
| Dosing in the studies[1,5,3] | TesamorelinDaily: 2 mg in phase 3; 1.4 mg on the current Egrifta SV label | CJC-1295 + IpamorelinSingle injections of CJC-1295 with DAC (half-life 5.8 to 8.1 days) |
What is the difference between tesamorelin and CJC-1295?
Both act on the GHRH receptor to make the pituitary release growth hormone. Tesamorelin is an approved drug (Egrifta) backed by large phase 3 trials. CJC-1295 has only small early human studies and is not approved. Ipamorelin, often paired with CJC-1295, works through a different receptor, the ghrelin receptor.[5,1,3,6]
Which has stronger evidence?
Tesamorelin, by a wide margin. Its phase 3 programme covered 806 people across two trials and measured visceral fat on scans for up to 52 weeks. CJC-1295's human data comes from small studies in healthy adults, and ipamorelin's one phase 2 trial found no benefit for its target, bowel recovery after surgery.[1,2,3,7]
Do they help with fat loss?
Tesamorelin reduced visceral (deep belly) fat by 15.2% over 26 weeks in people with HIV-associated lipodystrophy, but its label says it is not a weight-loss drug: overall body weight stayed about the same. The CJC-1295 and ipamorelin studies we cite did not measure fat or weight.[1,5,3,7]
How do the safety records compare?
Tesamorelin has a full FDA label, which says not to use it with active cancer, pituitary or hypothalamus problems, or pregnancy. No serious adverse reactions were reported in the CJC-1295 healthy-adult trials, but the FDA lists ipamorelin as a compounding safety risk, citing immune reactions and serious adverse event reports.[5,3,4]
Work out the units for your vial
Milligrams are not comparable between compounds, and the units on your syringe depend on your vial and how much water you add. Each guide has a chart for its common vial sizes.
Questions
Common questions
Is tesamorelin better than CJC-1295 with ipamorelin?
It is better studied and FDA-approved; whether it works better has never been tested, because no trial has compared them.
CJC-1295 with DAC vs no DAC: which was studied?
The human study cited here used the long-acting DAC version, which lasts days. The no-DAC version (modified GRF 1-29) is short-acting and is what blends with ipamorelin usually contain.
Is tesamorelin approved for anti-aging or bodybuilding?
No. Its only approved use is reducing excess abdominal fat in adults with HIV and lipodystrophy. Any other use is off-label.
Does ipamorelin raise cortisol?
In animal studies it released growth hormone without raising cortisol or ACTH, even at high doses, unlike older peptides such as GHRP-6. This has not been confirmed in long-term human trials.
Sources
- 1.Metabolic effects of a growth hormone-releasing factor in patients with HIV
Falutz J et al. N Engl J Med 2007;357:2359-2370 · Human trial - 2.Tesamorelin in HIV patients with excess abdominal fat: pooled phase 3 analysis
Falutz J et al. J Clin Endocrinol Metab 2010;95:4291-4304 · Human trial - 3.Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults
Teichman SL et al. J Clin Endocrinol Metab 2006;91:799-805 · Human trial - 4.FDA compounding safety-risk list
FDA. Bulk drug substances for compounding that may present significant safety risks (as of Apr 22, 2026) · FDA - 5.Egrifta SV label
FDA. Egrifta SV (tesamorelin) prescribing information, 2024 · FDA - 6.Ipamorelin, the first selective growth hormone secretagogue
Raun K et al. Eur J Endocrinol 1998;139:552-561 · Animal study - 7.Ipamorelin for postoperative ileus in bowel resection patients: a phase 2 trial
Beck DE et al. Int J Colorectal Dis 2014;29:1527-1534 · Human trial
Last reviewed Oct 4, 2026. Education only, not medical advice. PepDose sells no peptides.